^
    Apply
    Phase I Clinical Study of YL-15293 in Patients With Advanced Solid Tumor With KRAS Mutation (NCT05173805)
    Phase 1/2
    Shanghai YingLi Pharmaceutical Co. Ltd.
    Enrolling by invitation
    Last update posted :
    07/18/2023
    Initiation :
    01/30/2022
    Primary completion :
    04/30/2024
    Completion :
    12/30/2024
    PD-L1 • KRAS • MSI • PD-1
    |
    KRAS mutation • MSI-H/dMMR • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12A • KRAS G12
    |
    YL-15293
    A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation (NCT05119933)
    Phase 1/2
    Shanghai YingLi Pharmaceutical Co. Ltd.
    Recruiting
    Last update posted :
    11/15/2021
    Initiation :
    11/09/2021
    Primary completion :
    06/01/2023
    Completion :
    12/01/2023
    KRAS
    |
    KRAS G12C • KRAS G12
    |
    YL-15293